1. |
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
|
2. |
Rikova K, Guo AL, Zeng QF, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6): 1190-1203.
|
3. |
Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol, 2012, 13(10): 1011-1019.
|
4. |
Crinò L, Kim D, Riely GJ, et al. Initial phaseⅡ results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol, 2011, 29(S 15): 7514.
|
5. |
董江萍. FDA 批准克里唑替尼及其基因测试法治疗晚期非小细胞肺癌. 药物评价研究, 2011, 34(5): 402.
|
6. |
Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res, 2012, 22(11): 2109-2119.
|
7. |
Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012, 30(8): 863-870.
|
8. |
Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371(21): 1963-1971.
|